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f )	 Lifestyle: Diet & Exercise:	Involves	group	counselling	by	both	a	dietician	and	an	exercise	physiologist	weekly	for	one	month,	
monthly	for	the	next	three	months	and	three	monthly	thereafter.











e) Lifestyle: Exercise: Involves group counselling by an exercise physiologist weekly 
for ne month, monthly for the next three month  and three monthly thereafter. 
f) Lifestyle: Diet & Exercise: Involves group counselling by both a dietician and an 
exercise physiologist weekly for one month, monthly for the next three months and 
three monthly thereafter. 
4. Choice of comparator 
The comparator to the interventions is current practice. There is currently no systematic 
screening in place for pre-diabetes in Australia and no pharmaceutical treatments are 
approved for pre-diabetes on the PBS.  In determining the optimum mix of interventions, we 
assume none of the interventions of interest were currently in place.    
5. Intervention cost-effectiveness 
The int rv tions predomin t ly fall in the n rth- ast (‘health gain at a cost’) qua rant of th  
cost-effectiveness plane (Figure). A combined diet and exercise intervention has a greater 
probability of being cost-effective than either diet or exercise alone. Metformin has similar 
cost-effectiveness credentials to the diet and exercise intervention (Table). 
 
Figure: Cost-effectiveness of six diabetes prevention interventions aimed at people aged 45+ 




































Table: Cost-effectiveness ratios and probability of being cost-effective for the six diabetes 
prevention interventions when compared to current practice  
Intervention Average CER ($/DALY Averted) Uncertainty interval 
Diet & exercise $23,000 $19,000-$35,000 
Metformin $22,000 $17,000-$36,000 
Exercise $30,000 $23,000-$89,000 
Acarbose $37,000 $25,000-$134,000 
Diet $38,000 $23,000-$148,000 
Orlistat $100,000 $94,000-$130,000 
A combined diet & exercise intervention or metformin are the most cost-effective 
interventions. An incremental analysis of adding the two interventions together did not 
indicate ost-effectiveness, with an ICER of $67,000 per DALY to add diet & exercise to 
metformin. 
6. Conclusions 
Screening for pre-diabetes followed by diet & exercise or metformin is cost-effective and 
should be considered for in orporation into curr t practice. Workforc  capacity of dietitians 
and exercise physiologists to deliver lifestyle change interventions will need to be increased 
to appropriately support the intervention.  
7. ACE-Prevention 
To aid priority setting in prevention, the Assessing Cost-Effectiveness in Prevention Project 
(ACE-Prevention) applies standardised evaluation methods to assess the cost-effectiveness 
of 100 to 150 preventive interventions, taking a health sector perspective. This information is 
intended to help decision makers move resources from less efficient current practices to 
more efficient preventive action resulting in greater health gain for the same outlay. 
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